Systemic light-chain amyloidosis (AL) is caused by misfolded immunoglobulin light-chain
proteins that aggregate and deposit as unique fibrils, ultimately leading to organ failure and …

Background: Light chain (AL) amyloidosis is a rare disease in which deposits of insoluble
amyloid derived from immunoglobulin light chains accumulate and cause dysfunction of …

Abstract Purpose of Review Light chain (AL) amyloidosis is an insidious progressive
disease which results in significant morbidity and inevitable mortality if not diagnosed and …

Light chain amyloidosis (AL) results in tissue deposition of misfolded proteins, causing
organ dysfunction. In an era of modern therapies, such as bortezomib, reassessment of the …

In amyloid light-chain (AL) amyloidosis, a small plasma-cell clone, or less frequently a
mature B-cell clone, produces toxic monoclonal light chains that can be deposited in the …

Introduction: A systematic literature review on systemic light chain (AL) amyloidosis was
conducted in order to understand the disease burden, and identify unmet medical needs …

Aggressive treatment of AL amyloidosis with high dose intravenous melphalan followed by
autologous stem cell transplant (HDM/SCT) is effective in inducing hematologic and clinical …

Abstract 3150 Background: AL is a plasma cell dyscrasia characterized by the pathologic
production of monoclonal light chains which misfold, deposit in various organs, including the …

AL amyloidosis is characterized by a low-level expansion of an indolent, small plasma cell
clone that produces amyloidogenic light chains. Amyloid aggregates or preceding …

High-dose melphalan with stem-cell transplantation is believed to be the most effective
treatment for systemic light-chain (AL) amyloidosis, but many patients are ineligible because …